Transcranial ultrasonography as a predictor of disease progression in multiple sclerosis

Background Development of novel biomarkers for multiple sclerosis (MS) is of utmost importance to improve the capability to predict disease progression and disability. Transcranial ultrasonography (TCS) is a noninvasive imaging technique that allows the visualization of major parenchymal structures....

Full description

Saved in:
Bibliographic Details
Published inThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery Vol. 60; no. 1; pp. 16 - 5
Main Authors Fahmy, Ebtesam, Helmy, Hanan, Merghany, Nahla Aly, Ismail, Rania Shehata, Mounir, Nesma
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 02.02.2024
Springer Nature B.V
SpringerOpen
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Development of novel biomarkers for multiple sclerosis (MS) is of utmost importance to improve the capability to predict disease progression and disability. Transcranial ultrasonography (TCS) is a noninvasive imaging technique that allows the visualization of major parenchymal structures. This study aimed to evaluate the role of parenchymal transcranial sonography as a predictor for disease severity and progression in MS patients. Sixty patients with clinically definite Multiple sclerosis divided into two groups, relapsing–remitting MS (RRMS) group and chronic progressive MS (CPMS) group were included. Results There was a statistically significant increase in the mean diameters of the third ventricle, both frontal horns of lateral ventricle in RRMS and CPMS group compared to control values, and in CPMS group compared to RRMS group. Expanded Disability Status Scale (EDSS) score was significantly positively correlated with the diameter of right frontal horn of lateral ventricle in CPMS group. Linear regression analysis revealed that diameters of right frontal horn of lateral ventricle and third ventricle were independent predictors for MS severity. Conclusions TCS can be used as a simple noninvasive tool for prediction of disease severity and progression in MS patients.
ISSN:1110-1083
1687-8329
DOI:10.1186/s41983-024-00787-y